GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Incyte Corp (WBO:INCY) » Definitions » Cyclically Adjusted Price-to-FCF

Incyte (WBO:INCY) Cyclically Adjusted Price-to-FCF : 50.26 (As of Apr. 27, 2024)


View and export this data going back to 2017. Start your Free Trial

What is Incyte Cyclically Adjusted Price-to-FCF?

As of today (2024-04-27), Incyte's current share price is €70.36. Incyte's Cyclically Adjusted FCF per Share for the quarter that ended in Dec. 2023 was €1.40. Incyte's Cyclically Adjusted Price-to-FCF for today is 50.26.

The historical rank and industry rank for Incyte's Cyclically Adjusted Price-to-FCF or its related term are showing as below:

WBO:INCY' s Cyclically Adjusted Price-to-FCF Range Over the Past 10 Years
Min: 40.94   Med: 152.82   Max: 1631.5
Current: 40.98

During the past years, Incyte's highest Cyclically Adjusted Price-to-FCF was 1631.50. The lowest was 40.94. And the median was 152.82.

WBO:INCY's Cyclically Adjusted Price-to-FCF is ranked better than
60.4% of 101 companies
in the Biotechnology industry
Industry Median: 54.65 vs WBO:INCY: 40.98

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.

Incyte's adjusted free cash flow per share data for the three months ended in Dec. 2023 was €0.589. Add all the adjusted free cash flow per share for the past 10 years together and divide 10 will get our Cyclically Adjusted FCF per Share, which is €1.40 for the trailing ten years ended in Dec. 2023.

Shiller PE for Stocks: The True Measure of Stock Valuation


Incyte Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Incyte's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Incyte Cyclically Adjusted Price-to-FCF Chart

Incyte Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only 289.44 1,375.45 148.70 78.38 50.28

Incyte Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 78.38 75.24 56.77 49.06 50.28

Competitive Comparison of Incyte's Cyclically Adjusted Price-to-FCF

For the Biotechnology subindustry, Incyte's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Incyte's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Incyte's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Incyte's Cyclically Adjusted Price-to-FCF falls into.



Incyte Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Incyte's Cyclically Adjusted Price-to-FCF for today is calculated as

Cyclically Adjusted Price-to-FCF=Share Price/ Cyclically Adjusted FCF per Share
=70.36/1.4
=50.26

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Incyte's Cyclically Adjusted FCF per Share for the quarter that ended in Dec. 2023 is calculated as:

For example, Incyte's adjusted Free Cash Flow per Share data for the three months ended in Dec. 2023 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=0.589/129.4194*129.4194
=0.589

Current CPI (Dec. 2023) = 129.4194.

Incyte Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201403 -0.150 99.695 -0.195
201406 -0.102 100.560 -0.131
201409 0.070 100.428 0.090
201412 0.185 99.070 0.242
201503 -0.044 99.621 -0.057
201506 0.053 100.684 0.068
201509 -0.028 100.392 -0.036
201512 0.279 99.792 0.362
201603 0.429 100.470 0.553
201606 -0.298 101.688 -0.379
201609 0.361 101.861 0.459
201612 0.381 101.863 0.484
201703 -0.932 102.862 -1.173
201706 0.374 103.349 0.468
201709 0.074 104.136 0.092
201712 -0.458 104.011 -0.570
201803 0.032 105.290 0.039
201806 0.086 106.317 0.105
201809 0.692 106.507 0.841
201812 0.238 105.998 0.291
201903 0.560 107.251 0.676
201906 0.430 108.070 0.515
201909 1.197 108.329 1.430
201912 0.421 108.420 0.503
202003 -3.018 108.902 -3.587
202006 0.908 108.767 1.080
202009 0.502 109.815 0.592
202012 0.210 109.897 0.247
202103 0.598 111.754 0.693
202106 0.398 114.631 0.449
202109 0.853 115.734 0.954
202112 0.323 117.630 0.355
202203 0.809 121.301 0.863
202206 0.687 125.017 0.711
202209 1.210 125.227 1.251
202212 1.101 125.222 1.138
202303 -0.549 127.348 -0.558
202306 1.224 128.729 1.231
202309 0.567 129.860 0.565
202312 0.589 129.419 0.589

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Incyte  (WBO:INCY) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Incyte Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Incyte's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Incyte (WBO:INCY) Business Description

Industry
Traded in Other Exchanges
Address
1801 Augustine Cut-Off, Wilmington, DE, USA, 19803
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.